Transplant

Caring for older Americans’ teeth and gums is essential, but Medicare generally doesn’t cover that cost

Retrieved on: 
Friday, April 19, 2024

As dentistry scholars, we believe Koop also deserves credit for something else.

Key Points: 
  • As dentistry scholars, we believe Koop also deserves credit for something else.
  • Americans who rely on the traditional Medicare program for their health insurance get no help from that program with paying their dental bills aside from some narrow exceptions.
  • This group includes some 24 million people over 65 – about half of all the people who rely on Medicare for their health insurance.

‘Medically necessary’ exceptions

  • The list of circumstances that would lead patients to be eligible is short.
  • Some examples include patients scheduled for organ transplants or who have cancer treatment requiring radiation of their jaws.
  • But we believe that dental care is necessary for everyone, especially for older people.

Chew, speak, breathe

  • While many working Americans get limited dental coverage through their employers, those benefits are usually limited to as little as $1,000 per year.
  • And once they retire, Americans almost always lose even that basic coverage.
  • Rich Americans with Medicare coverage are almost three times more likely to receive dental care compared to those with low incomes.

Connected to many serious conditions

  • Having diabetes makes you three times as likely to develop gum disease because diabetes compromises the body’s response to inflammation and infection.
  • At the same time, treating diabetes patients for gum disease can help control their blood sugar levels.

Chemo can damage your teeth


Many cancer treatments can damage teeth, especially for older adults. As a result, Medicare has started to reimburse for dental bills tied to tooth decay or other oral conditions after they get chemotherapy or radiation treatment.

More than nice to have

  • Doctors and dentists are educated separately, and doctors learn very little about dental conditions and treatments when they’re in medical school.
  • Most dental electronic health records aren’t linked to medical systems, hindering comprehensive care and delivery of dental care to those in need.
  • Medical insurance was designed specifically to cover large, unpredictable expenses, while dental insurance was intended to mainly fund predictable and lower-cost preventive care.

Medicare Advantage plans

  • Until Medicare expands coverage to include preventive dental services for everyone, alternative plans such as Medicare Advantage, through which the federal government contracts with private insurers to provide Medicare benefits, serve as a stopgap.
  • In 2016, only 21% of beneficiaries in traditional Medicare had purchased a stand-alone dental plan, whereas roughly two-thirds of Medicare Advantage enrollees had at least some dental benefits through their coverage.


Frank Scannapieco is affiliated with The Task Force on Design and Analysis in Oral Health Research, and consults for the Colgate-Palmolive Company. Ira Lamster is a member of the Santa Fe Group. He currently receives consulting fees from Colgate, and research support from the CareQuest Institute.

EQS-News: HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell

Retrieved on: 
Wednesday, April 10, 2024

HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).

Key Points: 
  • HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).
  • "The positive results in terms of safety and tolerability confirm our intention to soon offer a drug that has the potential to revolutionize the treatment of severe liver diseases.
  • The data pave the way for further Phase II studies evaluating the efficacy of HRX-215 in humans," emphasizes Dr. Wolfgang Albrecht, COO of HepaRegeniX.
  • Further, HRX-215 was also able to protect hepatocytes from cell death in a model for acute liver injury.

EQS-News: ActiTrexx treats first patient with novel regulatory T cell therapy against Graft-versus-Host Disease

Retrieved on: 
Wednesday, April 10, 2024

GvHD is a severe and potentially life-threatening complication that can arise after an allogeneic haematopoietic stem cell transplantation and affects about 50 % of recipients.

Key Points: 
  • GvHD is a severe and potentially life-threatening complication that can arise after an allogeneic haematopoietic stem cell transplantation and affects about 50 % of recipients.
  • GvHD occurs when the stem cell donor’s T cells attack the patient’s tissues, leading to a range of symptoms that can affect the skin, gastrointestinal tract, and liver.
  • Prof. Dr. Andrea Tüttenberg, CEO of ActiTrexx, said: “GvHD can lead to life-long symptoms for the patient and is a major cause for the high mortality rate of blood stem cell transplantation.
  • Ten patients who have recently received a blood stem cell transplantation as treatment for leukemia will receive a single treatment with Actileucel.

Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus

Retrieved on: 
Thursday, April 4, 2024

BERKELEY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for CB-010, an allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (KO), for the treatment of lupus nephritis (LN) and extrarenal lupus (ERL). The Phase 1, multicenter, open label GALLOP clinical trial of CB-010 in patients with LN and ERL is expected to initiate by year-end 2024.

Key Points: 
  • The Phase 1, multicenter, open label GALLOP clinical trial of CB-010 in patients with LN and ERL is expected to initiate by year-end 2024.
  • CB-010 targets CD19, a protein on the surface of B cells, and has a PD-1 knockout (KO) that reduces CAR-T cell exhaustion.
  • CB-010 holds the potential for deep depletion of disease-causing B cells which could reset the immune system, leading to sustained drug-free remission.
  • Instead, the chRDNA technology allows for precise insertion of the CAR at an intended location within the T cell genome.

HNL Lab Medicine Unveils Lifesaving Cellular Therapy Laboratory

Retrieved on: 
Monday, April 1, 2024

ALLENTOWN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- HNL Lab Medicine, a leader in comprehensive laboratory services, proudly announces the grand opening of a state-of-the art Cellular Therapy Laboratory, made possible by a generous donation from the Hall family.

Key Points: 
  • ALLENTOWN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- HNL Lab Medicine, a leader in comprehensive laboratory services, proudly announces the grand opening of a state-of-the art Cellular Therapy Laboratory, made possible by a generous donation from the Hall family.
  • Designed to meet the increasing demand for personalized medicine and lifesaving therapies, the Tom and Karin Hall Cellular Therapy Laboratory is equipped with the latest technologies and staffed by a team of highly skilled experts.
  • The laboratory will focus on cellular therapy applications that were unavailable in the Lehigh Valley area.
  • HNL Lab Medicine has aligned with LVHN to create a clinical program, collection center, and cellular therapy laboratory.

Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update

Retrieved on: 
Wednesday, March 27, 2024

BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023.
  • Gamida Cell will become a private company, wholly owned by Highbridge, and the company’s outstanding ordinary shares are expected to be canceled.
  • The company has confirmed coverage with payers who cover more than 90% of commercial lives, exceeding the 2023 goal of 70%.
  • The full year Net Revenue included $1.1 million of net review for the fourth quarter of 2023.

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

Retrieved on: 
Monday, March 25, 2024

IRVINE, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the enrollment of the 12th participant on March 23, 2024, in the Company’s ongoing Phase 2 BESTOW trial assessing tegoprubart head-to-head with tacrolimus for the prevention of rejection in kidney transplantation.

Key Points: 
  • IRVINE, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the enrollment of the 12th participant on March 23, 2024, in the Company’s ongoing Phase 2 BESTOW trial assessing tegoprubart head-to-head with tacrolimus for the prevention of rejection in kidney transplantation.
  • In transplantation procedures, organ rejection is a major cause of graft failure, which can be a life-threatening condition.
  • Rejection occurs due to allorecognition, wherein the recipient's immune system identifies the transplanted organ as foreign tissue, triggering an immune response against the transplanted organ.
  • Calcineurin inhibitors (“CNIs”) are a critical component of most immunosuppressive regimens to prevent acute and long-term organ transplant rejection.

CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting

Retrieved on: 
Tuesday, April 9, 2024

CareDx, along with study collaborators from leading transplant centers, will present cutting-edge developments that underscore the clinical significance of CareDx’s cardiothoracic portfolio.

Key Points: 
  • CareDx, along with study collaborators from leading transplant centers, will present cutting-edge developments that underscore the clinical significance of CareDx’s cardiothoracic portfolio.
  • This includes AlloSure Heart, AlloMap Heart, HeartCare, AlloSure Lung, and AiCAV (in development); featured in over 25 oral presentations, posters, and two symposia.
  • These presentations will highlight real-world applications driving advancements in heart and lung transplantation.
  • “We are proud to have a leading presence once again at this pivotal heart and lung transplant meeting.

Valeos Welcomes Dr. Stuart Sweet to Board of Directors

Retrieved on: 
Tuesday, April 9, 2024

WASHINGTON, April 9, 2024 /PRNewswire/ -- Valeos, a 501(c)(3) nonprofit organization designed to improve organ transplant outcomes for patients and organ donors through data collaboration, today announced the appointment of Dr. Stuart C. Sweet, MD, PhD to its Board of Directors. Dr. Sweet is the W. McKim Marriott Professor of Pediatrics at Washington University in St. Louis, MO, and served as the 2016-2017 Board President of the Organ Procurement and Transplantation Network (OPTN), the U.S. national transplant system. Dr. Sweet spent more than two decades as the medical director of the pediatric lung transplant program at Washington University School of Medicine in St. Louis and St. Louis Children's Hospital, focusing clinically on pediatric lung transplantation and gaining expertise in organ allocation, clinical outcomes, health policy and the role of information technology in medicine.

Key Points: 
  • "I am honored to join the exceptional team at Valeos and continue my dedication to advancing the U.S. organ transplant system," said Dr. Sweet.
  • "We're excited to welcome Dr. Sweet to our Board of Directors.
  • This announcement follows an exciting year for Valeos, which saw its first appointments to its Board of Directors and Advisory Committee this past January.
  • With the backing of leading figures in healthcare, technology and government, Valeos is committed to building the world's largest de-identified transplant data sandbox.

ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, March 21, 2024

WINSTON-SALEM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the year ended December 31, 2023.

Key Points: 
  • WINSTON-SALEM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the year ended December 31, 2023.
  • In November, the Company announced Dr. Bruce Culleton assumed the role of the CEO and joined the ProKidney board of directors.
  • Dr. Culleton joined ProKidney in July 2023 as Executive Vice President of Clinical Development and Commercialization.
  • Mr. Periera-Kamath had previously joined ProKidney in July 2023 as Vice President of Business Development & Innovative Solutions.